Şenol Deniz, F. S. Et Al. 2024. Cholinesterase inhibitory and in silico toxicity assessment of thirty-four isoquinoline alkaloids – Berberine as the lead compound. CNS & NEUROLOGICAL DISORDERS - DRUG TARGETS , vol.23, no.6 , 773-783.

Şenol Deniz, F. S., Salmas, R. E., Emerce, E., Şener, B., & Erdoğan Orhan, İ., (2024). Cholinesterase inhibitory and in silico toxicity assessment of thirty-four isoquinoline alkaloids – Berberine as the lead compound. CNS & NEUROLOGICAL DISORDERS - DRUG TARGETS , vol.23, no.6, 773-783.

Şenol Deniz, FATMA Et Al. "Cholinesterase inhibitory and in silico toxicity assessment of thirty-four isoquinoline alkaloids – Berberine as the lead compound," CNS & NEUROLOGICAL DISORDERS - DRUG TARGETS , vol.23, no.6, 773-783, 2024

Şenol Deniz, FATMA S. Et Al. "Cholinesterase inhibitory and in silico toxicity assessment of thirty-four isoquinoline alkaloids – Berberine as the lead compound." CNS & NEUROLOGICAL DISORDERS - DRUG TARGETS , vol.23, no.6, pp.773-783, 2024

Şenol Deniz, F. S. Et Al. (2024) . "Cholinesterase inhibitory and in silico toxicity assessment of thirty-four isoquinoline alkaloids – Berberine as the lead compound." CNS & NEUROLOGICAL DISORDERS - DRUG TARGETS , vol.23, no.6, pp.773-783.

@article{article, author={FATMA SEZER ŞENOL DENİZ Et Al. }, title={Cholinesterase inhibitory and in silico toxicity assessment of thirty-four isoquinoline alkaloids – Berberine as the lead compound}, journal={CNS & NEUROLOGICAL DISORDERS - DRUG TARGETS}, year=2024, pages={773-783} }